BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17053051)

  • 1. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor.
    Wada Y; Lu R; Zhou D; Chu J; Przewloka T; Zhang S; Li L; Wu Y; Qin J; Balasubramanyam V; Barsoum J; Ono M
    Blood; 2007 Feb; 109(3):1156-64. PubMed ID: 17053051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.
    Burakoff R; Barish CF; Riff D; Pruitt R; Chey WY; Farraye FA; Shafran I; Katz S; Krone CL; Vander Vliet M; Stevens C; Sherman ML; Jacobson E; Bleday R
    Inflamm Bowel Dis; 2006 Jul; 12(7):558-65. PubMed ID: 16804392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis.
    Keino H; Watanabe T; Sato Y; Niikura M; Wada Y; Okada AA
    Arthritis Res Ther; 2008; 10(5):R122. PubMed ID: 18847496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.
    Wada Y; Cardinale I; Khatcherian A; Chu J; Kantor AB; Gottlieb AB; Tatsuta N; Jacobson E; Barsoum J; Krueger JG
    PLoS One; 2012; 7(4):e35069. PubMed ID: 22493730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn's Disease Mouse Model.
    Lv QK; Liu JX; Li SN; Gao YJ; Lv Y; Xu ZP; Huang BX; Xu SY; Yang DX; Zeng YL; Liu DF; Wang W
    Int J Mol Sci; 2015 Nov; 16(11):26654-66. PubMed ID: 26561804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency.
    Billich A
    IDrugs; 2007 Jan; 10(1):53-9. PubMed ID: 17187316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloantigen-reactive Th1 development in IL-12-deficient mice.
    Piccotti JR; Li K; Chan SY; Ferrante J; Magram J; Eichwald EJ; Bishop DK
    J Immunol; 1998 Feb; 160(3):1132-8. PubMed ID: 9570526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses.
    Kelsall BL; Stüber E; Neurath M; Strober W
    Ann N Y Acad Sci; 1996 Oct; 795():116-26. PubMed ID: 8958922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spermine differentially regulates the production of interleukin-12 p40 and interleukin-10 and suppresses the release of the T helper 1 cytokine interferon-gamma.
    Haskó G; Kuhel DG; Marton A; Nemeth ZH; Deitch EA; Szabó C
    Shock; 2000 Aug; 14(2):144-9. PubMed ID: 10947158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes.
    Trembleau S; Penna G; Gregori S; Gately MK; Adorini L
    Eur J Immunol; 1997 Sep; 27(9):2330-9. PubMed ID: 9341777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol.
    Pinto RA; Arredondo SM; Bono MR; Gaggero AA; Díaz PV
    Pediatrics; 2006 May; 117(5):e878-86. PubMed ID: 16618789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4(+) T cells from the Th1 to the Th2 pathway.
    Kim TS; Kang BY; Lee MH; Choe YK; Hwang SY
    Br J Pharmacol; 2001 Oct; 134(3):571-8. PubMed ID: 11588111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling.
    Cai X; Xu Y; Cheung AK; Tomlinson RC; Alcázar-Román A; Murphy L; Billich A; Zhang B; Feng Y; Klumpp M; Rondeau JM; Fazal AN; Wilson CJ; Myer V; Joberty G; Bouwmeester T; Labow MA; Finan PM; Porter JA; Ploegh HL; Baird D; De Camilli P; Tallarico JA; Huang Q
    Chem Biol; 2013 Jul; 20(7):912-21. PubMed ID: 23890009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response.
    Bliss J; Van Cleave V; Murray K; Wiencis A; Ketchum M; Maylor R; Haire T; Resmini C; Abbas AK; Wolf SF
    J Immunol; 1996 Feb; 156(3):887-94. PubMed ID: 8558014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.
    Cua DJ; Sherlock J; Chen Y; Murphy CA; Joyce B; Seymour B; Lucian L; To W; Kwan S; Churakova T; Zurawski S; Wiekowski M; Lira SA; Gorman D; Kastelein RA; Sedgwick JD
    Nature; 2003 Feb; 421(6924):744-8. PubMed ID: 12610626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of cyclophosphamide induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with the interleukin (IL)-12 antagonist IL-12(p40)2.
    Rothe H; O'Hara RM; Martin S; Kolb H
    Diabetologia; 1997 Jun; 40(6):641-6. PubMed ID: 9222642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases.
    Hölscher C
    Med Microbiol Immunol; 2004 Feb; 193(1):1-17. PubMed ID: 12836019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.
    Sands BE; Jacobson EW; Sylwestrowicz T; Younes Z; Dryden G; Fedorak R; Greenbloom S
    Inflamm Bowel Dis; 2010 Jul; 16(7):1209-18. PubMed ID: 19918967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in the Th1/Th2 phenotype of memory T-cell clones from rheumatoid arthritis synovium.
    Aarvak T; Chabaud M; Källberg E; Miossec P; Natvig JB
    Scand J Immunol; 1999 Jul; 50(1):1-9. PubMed ID: 10404044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody.
    Fuss IJ; Becker C; Yang Z; Groden C; Hornung RL; Heller F; Neurath MF; Strober W; Mannon PJ
    Inflamm Bowel Dis; 2006 Jan; 12(1):9-15. PubMed ID: 16374252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.